Rupa Mazumder | Toxicology and Pharmaceutical Science | Best Researcher Award

Best Researcher Award

Rupa Mazumder
Noida Institute of Engineering And Technology

Rupa Mazumder
Affiliation Noida Institute of Engineering And Technology
Country India
Scopus ID 7005832705
Documents 211
Citations 1,412
h-index 18
Subject Area Toxicology and Pharmaceutical Science
Event International Invention Awards
ORCID 0000-0002-1888-548X

Rupa Mazumder is a researcher affiliated with the Noida Institute of Engineering And Technology, India, whose documented scholarly profile is associated with toxicology and pharmaceutical science. The supplied Scopus record reports 211 documents, 1,412 citations, and an h-index of 18, providing a bibliometric basis for considering the researcher within an academic recognition framework. [1]

Abstract

Rupa Mazumder is an India-based researcher affiliated with the Noida Institute of Engineering And Technology and associated with the subject area of Toxicology and Pharmaceutical Science. The supplied bibliometric profile records 211 scholarly documents, 1,412 citations, and an h-index of 18. These indicators provide measurable evidence of sustained research activity and scholarly visibility. Her profile is considered in relation to the Best Researcher Award under the International Invention Awards framework. Assessment of researcher recognition may consider publication productivity, citation influence, research continuity, subject expertise, and the broader relevance of scientific contributions. Bibliometric information should be interpreted alongside verified qualitative evidence and individual research outputs for balanced academic evaluation.

Keywords

Rupa Mazumder; Best Researcher Award; Toxicology; Pharmaceutical Science; Drug Research; Pharmacology; Research Impact; Scholarly Publications; Citation Analysis; h-index; Scientific Research; International Invention Awards.

Introduction

Researcher recognition in pharmaceutical and toxicological sciences commonly involves consideration of scholarly productivity, research quality, citation performance, and sustained engagement with scientific questions. Bibliometric indicators can provide a structured quantitative perspective, although they do not independently establish the originality or practical significance of individual studies. The available profile for Rupa Mazumder presents a substantial publication and citation record that can be examined as part of a broader academic assessment. [1] Standardized researcher identifiers such as Scopus Author ID and ORCID can also assist in distinguishing scholarly outputs and improving the reliability of attribution. [2]

Research Profile

The supplied profile identifies Rupa Mazumder with the Noida Institute of Engineering And Technology in India and places the research activity within Toxicology and Pharmaceutical Science. The reported Scopus Author ID is 7005832705, while the associated ORCID is 0000-0002-1888-548X. These persistent identifiers provide complementary mechanisms for connecting scholarly records with an individual researcher and can support verification across academic databases. [1] [2]

Research Contributions

Within toxicology and pharmaceutical science, research contributions may encompass the investigation of drug effects, safety, pharmacological mechanisms, toxicological responses, therapeutic development, and related biomedical questions. The available information does not provide a complete thematic inventory of Rupa Mazumder’s individual studies, so specific scientific claims should be based on verified publication records rather than inferred solely from bibliometric indicators. The documented publication volume nevertheless indicates sustained participation in scholarly research. [1]

Publications

The supplied Scopus information records 211 documents associated with the researcher profile. Publication counts are useful for describing research productivity but should be evaluated with attention to document type, authorship, journal quality, research field, chronology, and subject relevance. A complete publication assessment would require examination of the underlying indexed records and individual bibliographic metadata. The reported document count is therefore presented as a profile-level bibliometric indicator rather than as an independent measure of research quality. [1]

Research Impact

The supplied profile reports 1,412 citations and an h-index of 18. Citation indicators can help describe the visibility and scholarly uptake of published research, while the h-index combines productivity and citation dimensions into a single metric. Such measures vary across disciplines, career stages, database coverage, and publication practices and should therefore be interpreted within appropriate academic context. [1] Citation-based assessment is strongest when complemented by qualitative evidence concerning originality, methodological contribution, collaboration, and influence on subsequent research.

Award Suitability

The available bibliometric information provides a relevant quantitative foundation for consideration for the Best Researcher Award. The combination of 211 reported documents, 1,412 citations, and an h-index of 18 indicates an established scholarly record within the supplied profile. [1] Final award suitability should, however, be determined through verification of the researcher identity, publication record, research quality, originality, professional contributions, and alignment with the applicable award criteria. The profile therefore supports consideration without implying that bibliometric measures alone determine award outcome.

Conclusion

Rupa Mazumder’s supplied academic profile documents substantial scholarly activity in the field of Toxicology and Pharmaceutical Science, with 211 documents, 1,412 citations, and an h-index of 18. These indicators establish a useful quantitative basis for academic recognition while requiring contextual interpretation. [1] Verification through persistent researcher identifiers, indexed publications, and qualitative evidence can strengthen the assessment. On the information provided, the profile presents a credible basis for consideration under the Best Researcher Award category of the International Invention Awards.

References

  1. Elsevier. (n.d.). Scopus author details: Rupa Mazumder, Author ID 7005832705. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=7005832705
  2. ORCID. (n.d.). ORCID record: Rupa Mazumder, ORCID 0000-0002-1888-548X. ORCID.
    https://orcid.org/0000-0002-1888-548X
  3. Journal article. (2026).Preparations, Applications, Patents, and Marketed Formulations of Nanoemulsions – A Comprehensive Review.
    http://dx.doi.org/10.2174/0122117385325186240912110731
  4. Journal article. (2025). A Comprehensive Investigation on the Role of Bioactives on DYRK1A to Avert Alzheimer’s Disease.
    https://doi.org/10.18311/jnr/2025/49903
  5. International Invention Awards. (2026. ). Official award website.
    https://inventionawards.org/

Pierre Constant Ntoutoume Nzoghe | Pharmacovigilance | Research Excellence Award

Dr. Pierre Constant Ntoutoume Nzoghe | Pharmacovigilance | Research Excellence Award

Mohammed V University, Gabon

Dr. Pierre Constant Ntoutoume Nzoghe is a PhD candidate in Pharmaceutical Sciences (2020–2026) at the Faculty of Medicine and Pharmacy of Rabat, Morocco, with prior degrees in Medicine Quality Control, Cellular and Molecular Biology, and a DEUG from Morocco, and a Baccalaureate (Series D) from Libreville. He currently serves as Quality Control Manager at Pharmaceutical Health, Libreville, and previously worked as an Analyst at Pharma5, specializing in physico-chemical (HPLC, IR, UV, Karl Fischer) and microbiological analyses. His experience includes internships in pharmacovigilance, biomedical laboratories, and industrial quality control across Morocco. His research focuses on adverse drug reactions, Stevens-Johnson Syndrome, and pharmacovigilance case reporting at the University Hospital of Libreville. He has presented multiple posters and oral communications at national and international congresses, including ISOP and SMPV, with publications in official congress booklets. He is also the author of a scientific publication on Fluconazole-induced Stevens-Johnson Syndrome and received the 3rd Prize for Best Poster Presentation at the 9th National and 2nd African Congress of Pharmacoeconomics and Pharmacoepidemiology.

Featured Publications

 

Dr. Natascia Bruni | Chemistry | Best Researcher Award

Dr. Natascia Bruni | Chemistry | Best Researcher Award

Candioli Pharma srl, Italy.

Natascia Bruni is an experienced regulatory compliance and quality management professional with over two decades of experience in the pharmaceutical and feed supplements industries. Currently, she serves as the Compliance Unit Director, Qualified Person, and QPPV at Acel Pharma srl, where she plays a pivotal role in ensuring regulatory compliance, managing product registrations, and overseeing pharmacovigilance activities. Throughout her career, Natascia has worked across various sectors, including pharmaceutical companies (human and veterinary), focusing on quality assurance, regulatory affairs, and strategic business compliance. She is well-versed in navigating complex regulatory landscapes and has made substantial contributions to corporate governance, legal risk management, and quality audits.

Profile

Scopus

Orcid

Education 🎓

Natascia Bruni's educational background demonstrates her deep expertise in both scientific and management fields, which has greatly contributed to her successful career in regulatory affairs and quality management. She completed her degree in Chemistry (Nuclear) at the University of Turin from 1991 to 1996, earning the highest distinction with a final vote of 110/110 con lode. This solid foundation in chemistry equipped her with a thorough understanding of chemical processes and analytical methods, which would later be pivotal in her regulatory and quality assurance roles in the pharmaceutical industry.

In addition to her scientific education, Natascia pursued specialized training in Regulatory Affairs and Pharmacovigilance for Drugs between 2001 and 2002, sharpening her skills in the complex regulatory frameworks governing drug safety and compliance. This training became essential in her role as a Qualified Person and QPPV in various pharmaceutical companies, where she led efforts to ensure products met both safety and regulatory standards.

Furthermore, Natascia completed a Business Management Course from 2015 to 2018, which enhanced her leadership, strategic planning, and operational management abilities. This course helped her integrate business and regulatory perspectives, allowing her to lead teams and drive organizational success in compliance-related activities.

Natascia also deepened her technical expertise by attending the School in Technology Enhanced Chemical Synthesis from 1996 to 1999, where she learned advanced techniques in chemical synthesis that continue to inform her work in pharmaceutical and feed supplement regulatory processes. Her multi-disciplinary education has provided a strong foundation for her leadership role in compliance and regulatory affairs, combining scientific rigor with strategic management skills.

Experience 💼

Compliance Unit Director - Qualified Person - QPPV (2012–Present), Acel Pharma srl (Candioli Group), Beinasco (Torino)
Responsible for ensuring the regulatory compliance of raw materials and finished products, overseeing registration/approvals, and managing import/export activities. Works closely with various departments to ensure that all products sold comply with national and international regulations.

Quality Unit Manager & Qualified Person (2007–2012), Olon Spa (Fidia Group), Rodano (MI) and Settimo Torinese (To)
Led the harmonization of QA/QC and regulatory procedures across two sites, ensuring GMP and regulatory compliance for the company’s product portfolio. Managed communications with health authorities and conducted quality audits for suppliers.

Chemistry Department Responsible (1997–1999), Antibiotic Spa, Settimo Torinese (To)
Conducted independent research and developed experimental procedures within the research project scope.

Researcher (1996–1997), Antibiotic Spa, Settimo Torinese (To)
Developed analytical methods and processes in the field of pharmaceutical research.

Research Interests 🔬

Regulatory Compliance in Pharmaceutical Products 📜

Natascia is particularly interested in the regulatory compliance of both raw materials and finished products in the pharmaceutical industry. Her work emphasizes the critical importance of navigating complex regulatory frameworks and ensuring that all pharmaceutical products, especially those used in veterinary medicine, comply with the highest standards of food safety, quality control, and marketing.

Pharmacovigilance & Product Registration 💊

A key area of Natascia's research is in pharmacovigilance, particularly focusing on the monitoring and reporting of adverse effects for drugs, ensuring products maintain safety and compliance throughout their lifecycle. She explores the processes involved in product registration, striving to streamline the approvals and regulatory checks necessary for market entry, particularly in international markets.

Process Improvement Methodologies 🔧

Natascia is also keen on exploring process improvement methodologies within the regulatory compliance space. Her work in this area aims to enhance operational efficiency, reduce legal risks, and strengthen internal control structures. By continuously improving regulatory and operational processes, she contributes to creating a safer and more efficient regulatory environment for pharmaceutical companies, particularly in the feed supplement and veterinary drug sectors.

Awards 🏅

University Senate Award: Best Academic Graduate (1996)
Awarded for excellence in academic performance by the Presidency Council of the Italian Chamber.

OPTIME Award: Best Experimental Dissertation of the Year (1996)
Recognized by the Industrial Union for outstanding research work.

Publications 📚

"Molecular Characterization of the Gorgonzola Cheese Mycobiota and Selection of a Putative Probiotic Saccharomyces cerevisiae var. boulardii for Evaluation as a Veterinary Feed Additive" Published in Applied Microbiology, 2024, 4(2), pp. 650–664.

"Efficacy of a Dietary Supplement in Dogs with Osteoarthritis: A Randomized Placebo-Controlled, Double-Blind Clinical Trial"
Published in PLoS ONE, 2022, 17(2), e0263971.

"Chronic Kidney Disease and Dietary Supplementation: Effects on Inflammation and Oxidative Stress", Published in Veterinary Sciences, 2021, 8(11), 277.
"Chronic Intestinal Disorders in Humans and Pets: Current Management and the Potential of Nutraceutical Antioxidants as Alternatives", Published in Animals, 2022, 12(7), 812.